BrightGene boosts stake in Suzhou GKE Gene Technology, waives Aoli Bio-Medical rights

BrightGene Bio-Medical Technology will increase its capital in Suzhou GKE Gene Technology Co., Ltd. by yuan 50,000,000, raising its ownership from 4.0816% to 12.8015%. This investment, approved by BrightGene's board of directors, involves subscribing to yuan 437,100 of new registered capital, with the remainder allocated to capital reserves. The transaction, based on an asset valuation of yuan 461,368,600 for GKE Gene Technology as of July 31, 2025, aligns with BrightGene's innovation-driven strategy.

In a related move, BrightGene has decided to waive its preferential right to subscribe to a capital increase in Shenzhen Aoli Bio-Medical Technology Co., Ltd., a company in which it holds 30.1664% equity. Shenzhen Aoli Bio-Medical Technology will issue new capital totaling yuan 80,000,000, with other investors increasing their capital. This decision will reduce BrightGene's stake in Shenzhen Aoli Bio-Medical Technology to 24.420458%, reflecting the company's overall strategic considerations. The auditor's reports for Suzhou GKE Gene Technology Co., Ltd. for 2024 and from January to September 2025 were also published.